Latest Regulatory News

Entropy Neurodynamics reports a 14.8% reduction in half-year losses while progressing a pioneering clinical trial for Binge Eating Disorder using its proprietary psychedelic drug TRP-8803. The company also secured $6.1 million in new funding and strategic collaborations to enhance its neuropsychiatry platform.

FIN Resources has completed the acquisition of the Cabin Lake Gold Project in Canada’s Northwest Territories, securing key permits and preparing for a fully funded drilling campaign starting in March 2026.

Hydrix Limited reported a 14% revenue decline and a sharp increase in net loss for H1 2026, raising concerns about its financial stability despite securing a major contract.

4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.

Mesoblast Limited reported its first commercial sales of FDA-approved Ryoncil, generating $48.7 million in net product sales for the half-year ended December 31, 2025, while reducing its net loss by 16%. The company also secured a $125 million five-year credit facility, restructuring its debt to support ongoing commercialization and development.

Coles Group reported a 2.5% revenue increase to $23.7 billion for the half year ended January 2026, driven by strong supermarket sales, but earnings were weighed down by a $235 million provision linked to a Fair Work Ombudsman ruling. The company declared a fully franked interim dividend of 41 cents per share.

Bubs Australia has delivered a robust first half for FY26, powered by a 48% revenue surge in the US, prompting an upgrade to its full-year earnings guidance.

Hubify has completed a strategic $250,000 placement at a striking 425% premium to fund its AI-first growth strategy, including a key partnership with HubLab to deliver AI-powered ICT and cybersecurity services.

Polymetals Resources has reported its maiden revenue from the Endeavor Mine with first concentrate shipments, yet posted a substantial half-year loss of $34.5 million. Operational setbacks and exploration advances mark a pivotal phase for the company.

TPG Telecom reported a robust FY25 with strategic asset sales, a major network sharing deal, and a $3 billion capital return, underpinning strong financial and sustainability progress.

Paradigm Biopharmaceuticals reports a sharp rise in half-year losses as it intensifies investment in its pivotal Phase 3 trial for knee osteoarthritis, setting sights on a critical interim analysis in mid-2026. The company also expands its osteoarthritis pipeline and maintains strong funding amid a strengthening biotech sector.

Basin Energy has executed a definitive agreement to sell its Marshall Uranium Project to Green Canada Corporation, securing upfront payments and retaining significant future upside through equity and buyback options.